Oncology

Orchard files for USD173 Million IPO to run pivotal gene therapy trials Orchard Therapeutics, Transatlantic biotech, has filed to raise USD 173 million in an IPO. This will lead it to take three gene therapies through the clinic. Orchard recognised itself as one of the broadest clinical-phase gene therapy pipelines in the industry when it added the portfolio of GlaxoSmithKline to its existing assets. Orchard carried out the GSK deal with a USD150 million series C to bolster its growing pipeline. Now, Orchard having around USD 200 million in cash following the series C, the slated USD 173 million will land itself in a robust position financially. Johnson & Johnson p...